DOASENSE - Home - Pioneering Point-of-Care Testing for DOACs

Go to content
Pioneering Novel Approaches to Testing for DOACs
 NEWS FLASH:
    • 2022-05: Editorial emphasizes the relevance of the DOAC Dipstick test [read more]

    • 2022-03: Latest data on the DOASENSE DOAC point-of-care test presented at GTH 2022, honored with Best Poster award [review congress presentations]

    • 2022-02: DOAC Dipstick testing can reliably exclude the presence of clinically relevant DOAC concentrations in plasma [download open access paper]

    • 2022-01: DOASENSE announces new partnership with Mediq as appointed exclusive distributor for Estonia [read more]

    • 2021-12: Value of DOASENSE's rapid POC test for DOACs mentioned in Australasian Anaesthesia Blue Book [download the Blue Book and refer to page 150]

    • 2021-09: First meta-analysis published on DOAC Dipstick for detection of Direct Oral Anticoagulants in patient urine samples [download open access paper]

    • 2021-05: DOASENSE rapid test suite for direct oral anticoagulants receives ANVISA approval in Brazil [read more]

    • 2021-04: Watch the recording of a great webinar on "DOAC Testing in Critical Care", organized by our partner Haemoview Diagnostics [watch the webinar here]


    • 2021-02: Germany’s Federal Joint Committee (Gemeinsamer Bundesausschuss G-BA) decided to expand the guideline for care of hip fractures to include regulations on testing for DOACs, mentions DOAC Dipstick as suitable test [read more]

READ ALL NEWS
[HERE]
When every minute counts … fast DOAC testing matters.

DOASENSE’s mission objective is changing the landscape of testing for DOACs (new synthetic oral anticoagulants) with novel and quick point-of-care urine tests

The determination of DOACs has long been limited to blood sampling approaches, with all their potential limitations, and a rapid assessment of the anticoagulant effect of non-vitamin K antagonist oral anticoagulants (Direct Oral AntiCoagulants – DOACs) by point-of-care testing (POCT) so far has been an unmet clinical need.


DOASENSE offers products for specific testing for DOACs in urine

Tests which are easy to use and easy to interpret, reproducible, and patient friendly

Listen to what opinion leaders think about DOASENSE's solutions:
Typical clinical scenarios where testing for specific DOACs can be of value

    • Stroke (e.g. before thrombolytic therapy)
    • Trauma
    • Emergency procedures
    • Evaluating for venous thromboembolism
    • Spontaneous hemorrhage
    • General surgery or invasive procedures
    • Other situations where medication history may not available

In each of these situations the objective is establishing the absence of DOACs in the patient prior to procedure

Please note that our products are for health care professional use only!
Divider
NOTE: DOASENSE(TM) products may not be available or approved in your country.


Copyright (c) 2016-2022 DOASENSE GmbH. All rights reserved.
Back to content